Inhibrx Biosciences, Inc
Price
OptionsOpen the Sheet →FilingsNewest: 8-K, Regulation FD disclosureSep 28 →InsidersNo open-market buys. 8 insiders sold $11.3M, 0 of 3 sales on a 10b5-1 plan.→HoldersMorgan Stanley 8.9%Perceptive 8.8%Sanofi 7.9%→Financing →PeersClosest companies: IMNM, TYRA, TECX→
From the filings
Figures
- Revenue
- $1.3Mlast 12 months
- Net income
- −$138.2Mlast 12 months
- Operating cash flow
- −$131.9Mlast 12 months
- Cash and equivalents
- $133.3Mat the last balance sheet
- Total debt
- $176.3Mat the last balance sheet
- Shares outstanding
- 14.7M shareson issue